Biologics Kill Biosimilars? Limited Originator Uptake Perplexes China Biogenerics Market

Although hope is high for the first follow-on biologic to take off in the world's second-largest pharma market, China's biosimilar developers see choppy waters ahead. Biosimilars are not only limited by uncertain pricing and murky interchangeability rules, but also by extremely low biologic penetration and developers rushing to develop I/O and cell therapies.